Hill-Rom Holdings, Inc.
Hill-Rom Holdings, Inc. HRC Peers
See (HRC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HRC | $155.96 | +0.03% | N/A | 41.92 | $3.72 | N/A |
| ISRG | $547.07 | -1.81% | 196.08B | 79.86 | $6.85 | N/A |
| BDXA | $59.24 | -2.24% | 50.10B | 21.44 | $2.76 | +2.29% |
| BDX | $173.10 | -2.02% | 49.61B | 33.55 | $5.16 | +2.29% |
| ALC | $87.54 | -0.60% | 43.30B | 42.70 | $2.05 | +0.38% |
| RMD | $245.77 | -0.96% | 36.04B | 27.58 | $8.91 | +0.87% |
| COO | $79.37 | -2.61% | 15.87B | 38.34 | $2.07 | N/A |
| BAX | $30.42 | -3.32% | 15.61B | -58.49 | -$0.52 | +3.01% |
| WST | $208.90 | -3.03% | 15.01B | 31.18 | $6.70 | +0.40% |
| BDXB | $48.16 | +1.39% | 13.69B | 7.60 | $6.33 | +2.29% |
Stock Comparison
HRC vs ISRG Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ISRG has a market cap of 196.08B. Regarding current trading prices, HRC is priced at $155.96, while ISRG trades at $547.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ISRG's P/E ratio is 79.86. In terms of profitability, HRC's ROE is +0.14%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, HRC is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs BDXA Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, BDXA has a market cap of 50.10B. Regarding current trading prices, HRC is priced at $155.96, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BDXA's P/E ratio is 21.44. In terms of profitability, HRC's ROE is +0.14%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, HRC is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs BDX Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, BDX has a market cap of 49.61B. Regarding current trading prices, HRC is priced at $155.96, while BDX trades at $173.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BDX's P/E ratio is 33.55. In terms of profitability, HRC's ROE is +0.14%, compared to BDX's ROE of +0.06%. Regarding short-term risk, HRC is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs ALC Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ALC has a market cap of 43.30B. Regarding current trading prices, HRC is priced at $155.96, while ALC trades at $87.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ALC's P/E ratio is 42.70. In terms of profitability, HRC's ROE is +0.14%, compared to ALC's ROE of +0.07%. Regarding short-term risk, HRC is less volatile compared to ALC. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs RMD Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, RMD has a market cap of 36.04B. Regarding current trading prices, HRC is priced at $155.96, while RMD trades at $245.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas RMD's P/E ratio is 27.58. In terms of profitability, HRC's ROE is +0.14%, compared to RMD's ROE of +0.25%. Regarding short-term risk, HRC is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs COO Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, COO has a market cap of 15.87B. Regarding current trading prices, HRC is priced at $155.96, while COO trades at $79.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas COO's P/E ratio is 38.34. In terms of profitability, HRC's ROE is +0.14%, compared to COO's ROE of +0.05%. Regarding short-term risk, HRC is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs BAX Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, BAX has a market cap of 15.61B. Regarding current trading prices, HRC is priced at $155.96, while BAX trades at $30.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BAX's P/E ratio is -58.49. In terms of profitability, HRC's ROE is +0.14%, compared to BAX's ROE of -0.08%. Regarding short-term risk, HRC is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs WST Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, WST has a market cap of 15.01B. Regarding current trading prices, HRC is priced at $155.96, while WST trades at $208.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas WST's P/E ratio is 31.18. In terms of profitability, HRC's ROE is +0.14%, compared to WST's ROE of +0.17%. Regarding short-term risk, HRC is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs BDXB Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, BDXB has a market cap of 13.69B. Regarding current trading prices, HRC is priced at $155.96, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BDXB's P/E ratio is 7.60. In terms of profitability, HRC's ROE is +0.14%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, HRC is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs HOLX Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, HOLX has a market cap of 12.22B. Regarding current trading prices, HRC is priced at $155.96, while HOLX trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas HOLX's P/E ratio is 23.03. In terms of profitability, HRC's ROE is +0.14%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, HRC is less volatile compared to HOLX. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs ATR Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ATR has a market cap of 10.33B. Regarding current trading prices, HRC is priced at $155.96, while ATR trades at $156.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ATR's P/E ratio is 28.60. In terms of profitability, HRC's ROE is +0.14%, compared to ATR's ROE of +0.15%. Regarding short-term risk, HRC is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs MASI Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, MASI has a market cap of 8.10B. Regarding current trading prices, HRC is priced at $155.96, while MASI trades at $149.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MASI's P/E ratio is -26.07. In terms of profitability, HRC's ROE is +0.14%, compared to MASI's ROE of -0.41%. Regarding short-term risk, HRC is less volatile compared to MASI. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs RGEN Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, RGEN has a market cap of 6.75B. Regarding current trading prices, HRC is priced at $155.96, while RGEN trades at $120.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas RGEN's P/E ratio is -286.19. In terms of profitability, HRC's ROE is +0.14%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, HRC is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs STVN Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, STVN has a market cap of 6.55B. Regarding current trading prices, HRC is priced at $155.96, while STVN trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas STVN's P/E ratio is 46.15. In terms of profitability, HRC's ROE is +0.14%, compared to STVN's ROE of +0.09%. Regarding short-term risk, HRC is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs MMSI Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, MMSI has a market cap of 5.70B. Regarding current trading prices, HRC is priced at $155.96, while MMSI trades at $96.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MMSI's P/E ratio is 47.30. In terms of profitability, HRC's ROE is +0.14%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, HRC is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs TFX Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, TFX has a market cap of 5.38B. Regarding current trading prices, HRC is priced at $155.96, while TFX trades at $121.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas TFX's P/E ratio is 37.72. In terms of profitability, HRC's ROE is +0.14%, compared to TFX's ROE of +0.03%. Regarding short-term risk, HRC is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs BLCO Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, BLCO has a market cap of 3.96B. Regarding current trading prices, HRC is priced at $155.96, while BLCO trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BLCO's P/E ratio is -10.98. In terms of profitability, HRC's ROE is +0.14%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, HRC is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs HAE Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, HAE has a market cap of 3.36B. Regarding current trading prices, HRC is priced at $155.96, while HAE trades at $66.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas HAE's P/E ratio is 20.21. In terms of profitability, HRC's ROE is +0.14%, compared to HAE's ROE of +0.18%. Regarding short-term risk, HRC is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs ICUI Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ICUI has a market cap of 3.22B. Regarding current trading prices, HRC is priced at $155.96, while ICUI trades at $130.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ICUI's P/E ratio is -27.07. In terms of profitability, HRC's ROE is +0.14%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, HRC is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs XRAY Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, XRAY has a market cap of 3.15B. Regarding current trading prices, HRC is priced at $155.96, while XRAY trades at $15.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas XRAY's P/E ratio is -3.54. In terms of profitability, HRC's ROE is +0.14%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, HRC is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs WRBY Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, WRBY has a market cap of 2.43B. Regarding current trading prices, HRC is priced at $155.96, while WRBY trades at $20.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas WRBY's P/E ratio is -117.88. In terms of profitability, HRC's ROE is +0.14%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, HRC is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs QDEL Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, QDEL has a market cap of 2.00B. Regarding current trading prices, HRC is priced at $155.96, while QDEL trades at $29.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas QDEL's P/E ratio is -5.66. In terms of profitability, HRC's ROE is +0.14%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, HRC is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs NVCR Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, NVCR has a market cap of 1.98B. Regarding current trading prices, HRC is priced at $155.96, while NVCR trades at $17.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NVCR's P/E ratio is -11.75. In terms of profitability, HRC's ROE is +0.14%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, HRC is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs LMAT Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, LMAT has a market cap of 1.84B. Regarding current trading prices, HRC is priced at $155.96, while LMAT trades at $81.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas LMAT's P/E ratio is 41.37. In terms of profitability, HRC's ROE is +0.14%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, HRC is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs ATRC Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ATRC has a market cap of 1.65B. Regarding current trading prices, HRC is priced at $155.96, while ATRC trades at $33.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ATRC's P/E ratio is -41.06. In terms of profitability, HRC's ROE is +0.14%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, HRC is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs AZTA Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, AZTA has a market cap of 1.26B. Regarding current trading prices, HRC is priced at $155.96, while AZTA trades at $27.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas AZTA's P/E ratio is -8.40. In terms of profitability, HRC's ROE is +0.14%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, HRC is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs KMTS Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, KMTS has a market cap of 1.19B. Regarding current trading prices, HRC is priced at $155.96, while KMTS trades at $23.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas KMTS's P/E ratio is -12.03. In terms of profitability, HRC's ROE is +0.14%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, HRC is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs PLSE Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, PLSE has a market cap of 1.16B. Regarding current trading prices, HRC is priced at $155.96, while PLSE trades at $17.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas PLSE's P/E ratio is -18.80. In terms of profitability, HRC's ROE is +0.14%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, HRC is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs BLFS Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, BLFS has a market cap of 1.05B. Regarding current trading prices, HRC is priced at $155.96, while BLFS trades at $22.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas BLFS's P/E ratio is -88.36. In terms of profitability, HRC's ROE is +0.14%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, HRC is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs STAA Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, STAA has a market cap of 913.76M. Regarding current trading prices, HRC is priced at $155.96, while STAA trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas STAA's P/E ratio is -12.81. In terms of profitability, HRC's ROE is +0.14%, compared to STAA's ROE of -0.18%. Regarding short-term risk, HRC is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs ATRI Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ATRI has a market cap of 809.44M. Regarding current trading prices, HRC is priced at $155.96, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ATRI's P/E ratio is 64.50. In terms of profitability, HRC's ROE is +0.14%, compared to ATRI's ROE of +0.05%. Regarding short-term risk, HRC is less volatile compared to ATRI. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs ANGO Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ANGO has a market cap of 388.61M. Regarding current trading prices, HRC is priced at $155.96, while ANGO trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ANGO's P/E ratio is -9.48. In terms of profitability, HRC's ROE is +0.14%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, HRC is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs NNNN Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, NNNN has a market cap of 342.35M. Regarding current trading prices, HRC is priced at $155.96, while NNNN trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NNNN's P/E ratio is 260.00. In terms of profitability, HRC's ROE is +0.14%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, HRC is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs NYXH Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, NYXH has a market cap of 276.81M. Regarding current trading prices, HRC is priced at $155.96, while NYXH trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NYXH's P/E ratio is -3.63. In terms of profitability, HRC's ROE is +0.14%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, HRC is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs SMTI Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, SMTI has a market cap of 275.70M. Regarding current trading prices, HRC is priced at $155.96, while SMTI trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas SMTI's P/E ratio is -27.21. In terms of profitability, HRC's ROE is +0.14%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, HRC is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs OSUR Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, OSUR has a market cap of 190.37M. Regarding current trading prices, HRC is priced at $155.96, while OSUR trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas OSUR's P/E ratio is -6.06. In terms of profitability, HRC's ROE is +0.14%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, HRC is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs STXS Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, STXS has a market cap of 175.44M. Regarding current trading prices, HRC is priced at $155.96, while STXS trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas STXS's P/E ratio is -6.58. In terms of profitability, HRC's ROE is +0.14%, compared to STXS's ROE of -2.17%. Regarding short-term risk, HRC is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs UTMD Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, UTMD has a market cap of 173.19M. Regarding current trading prices, HRC is priced at $155.96, while UTMD trades at $53.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas UTMD's P/E ratio is 14.07. In terms of profitability, HRC's ROE is +0.14%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, HRC is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs ZTEK Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ZTEK has a market cap of 164.81M. Regarding current trading prices, HRC is priced at $155.96, while ZTEK trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ZTEK's P/E ratio is -19.75. In terms of profitability, HRC's ROE is +0.14%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, HRC is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs PDEX Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, PDEX has a market cap of 144.79M. Regarding current trading prices, HRC is priced at $155.96, while PDEX trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas PDEX's P/E ratio is 16.09. In terms of profitability, HRC's ROE is +0.14%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, HRC is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs KRMD Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, KRMD has a market cap of 129.19M. Regarding current trading prices, HRC is priced at $155.96, while KRMD trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas KRMD's P/E ratio is -23.33. In terms of profitability, HRC's ROE is +0.14%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, HRC is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs INFU Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, INFU has a market cap of 126.48M. Regarding current trading prices, HRC is priced at $155.96, while INFU trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas INFU's P/E ratio is 54.82. In terms of profitability, HRC's ROE is +0.14%, compared to INFU's ROE of +0.08%. Regarding short-term risk, HRC is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs ZJYL Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, ZJYL has a market cap of 125.11M. Regarding current trading prices, HRC is priced at $155.96, while ZJYL trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas ZJYL's P/E ratio is 39.96. In terms of profitability, HRC's ROE is +0.14%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, HRC is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs MBOT Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, MBOT has a market cap of 92.40M. Regarding current trading prices, HRC is priced at $155.96, while MBOT trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MBOT's P/E ratio is -3.97. In terms of profitability, HRC's ROE is +0.14%, compared to MBOT's ROE of -0.85%. Regarding short-term risk, HRC is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs MLSS Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, MLSS has a market cap of 78.87M. Regarding current trading prices, HRC is priced at $155.96, while MLSS trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MLSS's P/E ratio is -16.75. In terms of profitability, HRC's ROE is +0.14%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, HRC is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs AKYA Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, AKYA has a market cap of 64.84M. Regarding current trading prices, HRC is priced at $155.96, while AKYA trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas AKYA's P/E ratio is -1.35. In terms of profitability, HRC's ROE is +0.14%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, HRC is less volatile compared to AKYA. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs OMIC Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, OMIC has a market cap of 50.77M. Regarding current trading prices, HRC is priced at $155.96, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas OMIC's P/E ratio is -0.58. In terms of profitability, HRC's ROE is +0.14%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, HRC is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for HRC.
HRC vs IGAP Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, IGAP has a market cap of 50.23M. Regarding current trading prices, HRC is priced at $155.96, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas IGAP's P/E ratio is -10.52. In terms of profitability, HRC's ROE is +0.14%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, HRC is less volatile compared to IGAP. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs DXR Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, DXR has a market cap of 37.52M. Regarding current trading prices, HRC is priced at $155.96, while DXR trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas DXR's P/E ratio is -86.19. In terms of profitability, HRC's ROE is +0.14%, compared to DXR's ROE of +0.02%. Regarding short-term risk, HRC is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs POCI Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, POCI has a market cap of 32.27M. Regarding current trading prices, HRC is priced at $155.96, while POCI trades at $4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas POCI's P/E ratio is -6.48. In terms of profitability, HRC's ROE is +0.14%, compared to POCI's ROE of -0.54%. Regarding short-term risk, HRC is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs SDC Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, SDC has a market cap of 29.11M. Regarding current trading prices, HRC is priced at $155.96, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas SDC's P/E ratio is -0.03. In terms of profitability, HRC's ROE is +0.14%, compared to SDC's ROE of -1.96%. Regarding short-term risk, HRC is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs FEMY Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, FEMY has a market cap of 27.51M. Regarding current trading prices, HRC is priced at $155.96, while FEMY trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas FEMY's P/E ratio is -1.11. In terms of profitability, HRC's ROE is +0.14%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, HRC is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs IVC Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, IVC has a market cap of 24.91M. Regarding current trading prices, HRC is priced at $155.96, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas IVC's P/E ratio is -0.79. In terms of profitability, HRC's ROE is +0.14%, compared to IVC's ROE of -0.46%. Regarding short-term risk, HRC is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs NXGLW Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, NXGLW has a market cap of 24.47M. Regarding current trading prices, HRC is priced at $155.96, while NXGLW trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NXGLW's P/E ratio is -0.26. In terms of profitability, HRC's ROE is +0.14%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, HRC is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs NEPH Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, NEPH has a market cap of 23.96M. Regarding current trading prices, HRC is priced at $155.96, while NEPH trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NEPH's P/E ratio is 28.25. In terms of profitability, HRC's ROE is +0.14%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, HRC is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs RVP Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, RVP has a market cap of 18.97M. Regarding current trading prices, HRC is priced at $155.96, while RVP trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas RVP's P/E ratio is -1.58. In terms of profitability, HRC's ROE is +0.14%, compared to RVP's ROE of -0.27%. Regarding short-term risk, HRC is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs NXGL Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, NXGL has a market cap of 17.15M. Regarding current trading prices, HRC is priced at $155.96, while NXGL trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NXGL's P/E ratio is -4.98. In terms of profitability, HRC's ROE is +0.14%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, HRC is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs HBIO Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, HBIO has a market cap of 14.42M. Regarding current trading prices, HRC is priced at $155.96, while HBIO trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas HBIO's P/E ratio is -0.25. In terms of profitability, HRC's ROE is +0.14%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, HRC is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs LUCYW Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, LUCYW has a market cap of 13.82M. Regarding current trading prices, HRC is priced at $155.96, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas LUCYW's P/E ratio is N/A. In terms of profitability, HRC's ROE is +0.14%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, HRC is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs MHUA Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, MHUA has a market cap of 11.72M. Regarding current trading prices, HRC is priced at $155.96, while MHUA trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas MHUA's P/E ratio is 0.93. In terms of profitability, HRC's ROE is +0.14%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, HRC is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs WOK Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, WOK has a market cap of 10.16M. Regarding current trading prices, HRC is priced at $155.96, while WOK trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas WOK's P/E ratio is -2.58. In terms of profitability, HRC's ROE is +0.14%, compared to WOK's ROE of -0.30%. Regarding short-term risk, HRC is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs POAI Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, POAI has a market cap of 9.74M. Regarding current trading prices, HRC is priced at $155.96, while POAI trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas POAI's P/E ratio is -0.55. In terms of profitability, HRC's ROE is +0.14%, compared to POAI's ROE of -5.91%. Regarding short-term risk, HRC is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs LUCY Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, LUCY has a market cap of 8.27M. Regarding current trading prices, HRC is priced at $155.96, while LUCY trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas LUCY's P/E ratio is 0.06. In terms of profitability, HRC's ROE is +0.14%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, HRC is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs EKSO Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, EKSO has a market cap of 7.33M. Regarding current trading prices, HRC is priced at $155.96, while EKSO trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas EKSO's P/E ratio is -0.53. In terms of profitability, HRC's ROE is +0.14%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, HRC is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs NSTG Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, NSTG has a market cap of 5.07M. Regarding current trading prices, HRC is priced at $155.96, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas NSTG's P/E ratio is -0.03. In terms of profitability, HRC's ROE is +0.14%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, HRC is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs GCTK Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, GCTK has a market cap of 4.01M. Regarding current trading prices, HRC is priced at $155.96, while GCTK trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas GCTK's P/E ratio is N/A. In terms of profitability, HRC's ROE is +0.14%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, HRC is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs STSS Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, STSS has a market cap of 3.88M. Regarding current trading prices, HRC is priced at $155.96, while STSS trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas STSS's P/E ratio is -0.51. In terms of profitability, HRC's ROE is +0.14%, compared to STSS's ROE of -0.99%. Regarding short-term risk, HRC is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs GMVD Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, GMVD has a market cap of 1.80M. Regarding current trading prices, HRC is priced at $155.96, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas GMVD's P/E ratio is -0.01. In terms of profitability, HRC's ROE is +0.14%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, HRC is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs GMVDW Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, GMVDW has a market cap of 1.80M. Regarding current trading prices, HRC is priced at $155.96, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas GMVDW's P/E ratio is N/A. In terms of profitability, HRC's ROE is +0.14%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, HRC is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.
HRC vs AVGR Comparison
HRC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HRC stands at N/A. In comparison, AVGR has a market cap of 1.52M. Regarding current trading prices, HRC is priced at $155.96, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HRC currently has a P/E ratio of 41.92, whereas AVGR's P/E ratio is -0.05. In terms of profitability, HRC's ROE is +0.14%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, HRC is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for HRC.